Obama awards Presidential Medal of Freedom to 18

SCNow - 2 days ago
Musician Stevie Wonder celebrates...

Doctor who founded Ohio Wildlife Center dead at 63

Columbus Dispatch - 5 days ago
Through the years, its services...

Heartbeats: Hospital to hold dedication

MyCentralJersey.com - 1 week ago
Saint Peter's University...

What the Recent Run-Up in Ebola Stocks Taught Investors

Equities.com - 1 week ago
TLSR: I think we're seeing a...

TSX Mining Stock News: Nevada Sunrise (TSXV: NEV) Agreement on the ...

InvestorIdeas.com (press release) - 1 week ago
Nevada Sunrise has recently...

100 things to know about Medicare and Medicaid

Becker's Hospital Review - 2 weeks ago
President Nixon expanded Medicare...

Georgia Lawmakers Reveal New Medical Marijuana Bill for 2015

The Daily Chronic - 2 weeks ago
Please encourage your fellow...

Amazon Begins Extending Prime-Member Perks to Other Shopping Sites

Re/code - 3 weeks ago
The move underscores the growing...

Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining

Seeking Alpha (registration) - 2 weeks ago
TLSR: I think we're seeing a...

Checkpoint Systems, Inc. Announces Third Quarter 2014 Results

Business Wire (press release) - 3 weeks ago
Apparel Labeling Solutions (ALS)...

News via Google. See more news matching 'als expanded access'

 

Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.